Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief Executive Officer (CEO). Formerly known as HpVac, the Company has repositioned itself under the new name Atopia Therapeutics to better reflect its commitment to addressing the…
Study results indicate beneficial effects on airway hyperresponsiveness, remodeling and inflammation Geneva, Switzerland, March 27, 2023 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced positive results of its lead compound HpVac-R13 on airway hyperresponsiveness and inflammation in a murine model of allergic asthma. At…
Major milestone for accelerating the development of HpVac-13 in allergic diseases Geneva, Switzerland, October 17, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced novel data on its lead compound HpVac-13 for the treatment and prevention of asthmatic attacks in an animal disease model…